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Introduction
Several members of the ATP-binding cassette (ABC) superfamily of transporters are involved in the transport of both endogenous and xenobiotic compounds from major organs in the body (Borst and Oude Elferink, 1992 ). An example is the multidrug resistance protein 2 (MRP2 or ABCC2). MRP2 protein has mainly been detected in the apical plasma membrane of hepatocytes, kidney proximal tubules and intestine (Paulusma et al., 1997; Mottino et al., 2001; Schaub et al., 1999) . In addition, MRP2 is localized in lung, gallbladder, and placental trophoblasts (St-Pierre et al., 2000; Rost et al., 2001; Konig et al., 2003) .
The substrate specificity of MRP2 is broad and includes glutathione-, glucuronide-and sulfate conjugates of many drugs, some non-conjugated organic anions, and various neutral or positively charged drugs (Konig et al., 2003) . Known high affinity physiological substrates of MRP2 are glucuronides of the hemoglobin breakdown product bilirubin (Kamisako et al., 1999) .
In humans, mutations in the MRP2 gene can result in the autosomal recessive Dubin-Johnson syndrome (DJS). The primary defect in patients with DJS is a mild conjugated hyperbilirubinemia, caused by the impaired hepatobiliary transport system of non-bile salt organic anions across the canalicular membrane (Oude Elferink and Groen, 2002) . Although in general DJS is an extremely rare disorder, it is relatively frequent in Iranian Jews, where the prevalence in 1:1300. Several mutations have been reported in patients with DJS, resulting in absence of MRP2 or intracellular trafficking defects (Suzuki and Sugiyama, 2002) .
The animal models for DJS are the Groningen Yellow (GY)/Transporter deficient (TR -) and Eisai Hyperbilirubinemic (EHBR) rat strains, spontaneous mutants from the Wistar and Sprague-Dawley strains, respectively (Jansen et al., 1985; Hosokawa et al., 1992) . The Mrp2 mutation in the TR -rats is a single nucleotide deletion leading to a JPET # 98665 frameshift and a stop codon (Paulusma et al., 1996) . In EHBR rats, a one nucleotide substitution results in a stop codon (Ito et al., 1997) . Both mutant rat strains have been extensively characterized and main differences between the mutant and wild type rats are a decreased bile flow, increased plasma levels of bilirubin glucuronides, a strong reduction in the biliary secretion of reduced glutathione, and a range of glutathione-, glucuronide-, and sulfate conjugates, and unconjugated compounds (Oude Elferink et al., 1995; Konig et al., 2003) .
The phenotype of patients with DJS and Mrp2 deficient rats is relatively mild and life expectancy is not significantly affected (Oude Elferink et al., 1995) . This is most likely explained by the strong induction of MRP3 (ABCC3) in hepatocytes under conditions where the function of MRP2 is impaired (Hirohashi et al., 1998; Konig et al., 1999) .
MRP3 is localized in the sinusoidal membrane and, recently, it has been shown that bilirubin glucuronides are substrates for human MRP3 (Lee et al., 2004) . In the absence of a functional MRP2, MRP3 compensates for the lack of MRP2-mediated transport by exporting at least part of the intra-hepatically formed bilirubin glucuronides into the blood. In normal human liver, MRP3 protein was mainly detected in the bile ducts and not in hepatocytes (Scheffer et al., 2002) . In addition, MRP3 protein was found in adrenal gland, kidney and intestine.
Analysis of TR -and EHBR rats has resulted in a wealth of information regarding the function and substrate specificity of Mrp2 and has demonstrated the importance of this transporter in the biliary and renal elimination of many drugs, like for example pravastatin and SN38 (an active metabolite of irinotecan) (Chu et al., 1997; Yamazaki et al., 1997) . Interpretation of data obtained with TR -and EHBR rats was in some cases complicated by the induction of Mrp3, UGT1a and significant differences in cytochrome P450 enzyme levels between wild type and mutant strains (Jager et al., 1998; Newton et al., 2005; Johnson et al., 2005) . The availability of additional in vivo models to study the JPET # 98665
Methods
Animals
Mrp2
-/-mice were generated by Deltagen, Inc. (San Carlos, CA) . Briefly, the Mrp2 gene was inactivated by homologous recombination in ES cells derived from the 129/OlaHsd mouse substrain by deletion of nucleotides 1886-1897 of the coding sequence of the Mrp2 gene and introduction of a LacZ-Neo cassette. F1 mice were generated by breeding with C57BL/6 females. Heterozygous offspring of the F1 generation was used for re-derivation by embryo transfer at Taconic Farms (Germantown, NY). Post-derivation, mice were backcrossed for eight generations to a Taconic C57BL/6 background. Mice used in this manuscript were from heterozygote x heterozygote crosses of F2 mice. All mice were maintained at Taconic in a sterile isolator and monitored to verify their germfree/defined flora condition. Animals were kept in a temperature controlled environment with a 12 h light/12 h dark cycle. Animals received food and water ad libitum. All animal handling was according to Animal Procedure Statements approved by the Merck Rahway Institutional Animal Care and Use Committee.
Mice were genotyped by PCR analysis of purified tail DNA. Wild type Mrp2 was detected with oligo nucleotides GS(E) 5'gttcagcacctaacagaggtgattg3' and GS(E, T)
5'tcctgaggaagagctggaaagcaag3', and the knock-out allele was detected with oligonucleotides NEO(T) 5'gggtgggattagataaatgcctgctct3' and GS(E, T), resulting in fragments of 237 and 502 bp, respectively (see Figure 1A ).
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cage with three to four groups for each study. During urine collection, samples were kept on ice and in the dark. Serum and urine chemistry parameters listed in Tables 1 and 2 were determined using a Hitachi 911 clinical chemistry analyzer (Roche Diagnostics, Indianapolis, IN). Sodium, potassium and chloride levels were determined using ionspecific electrodes. Other tests were performed by standard biochemical methods.
Analysis of bilirubin glucuronides and total glutathione
Male Mrp2 -/-and wild type mice (between 20-24 weeks of age) were used in this study. The animals were fasted overnight with free access to water. Mice were anesthetized via isoflurane inhalation, administered at a rate of 2% in oxygen at 0.5 L/min during the surgical procedure. The bile duct was catheterized and the gallbladder was ligated and removed. After a recovery period of 1-3 hrs, the bile samples were collected on ice at 0-15, 15-30, 30-45, and 45-60 min. For measurement of bilirubin glucuronides, the bile samples were collected in the dark and immediately immersed in liquid nitrogen until analysis. Direct bilirubin (bilirubin glucuronides) in bile were analyzed with a Stanbio direct bilirubin assay kit (Stanbio Laboratory, Boerne, Texas). Total glutathione (reduced plus oxidized) in bile was measured using a Glutathione Assay Kit (Sigma Chemical Co., St. Louis, MO). Glutathione in liver extracts and plasma was determined using the same kit.
Western blotting
Crude plasma membranes were prepared from mouse liver and kidney homogenates as described previously (Kobayashi et al., 1990 Tables 4-1 and 4-2) .
Samples were applied to Low-Density Microarrays by centrifugation twice for 1 min at 1200 g. RT products from the pooled cDNAs of three animals were analyzed in three independent experiments. Real-time quantitative PCR was performed using an ABI Alto, CA) and eluted at a flow rate of 2 ml/min. The mobile phase consisted of a mixture of buffer A (10 mM ammonium acetate) and buffer B (10 mM ammonium acetate in 90% acetonitrile and 10% methanol). A linear gradient elution with buffer B was run from 20 to 60% in 16 min and chromatographic peaks of testosterone and its metabolites were monitored at 254 nm at the following retention times: 6β-hydroxytestosterone at 5.3 min, 7α-hydroxytestosterone at 4.5 min, 16α-hydroxytestosterone at 6.4 min, and 2α-hydroxytestosterone at 7.1 min.
Biliary excretion and pharmacokinetics of dibromosulfophthalein (DBSP)
Male Mrp2 -/-and wild type mice (between 20-24 weeks of age) were used. The animals were fasted overnight with free access to water. DBSP (Laboratoire SERB, 
Quantification of DBSP in bile and blood
Briefly, aliquots of bile (10 µl) were diluted with 50 mM Tris-HCl buffer (pH 7.4), and then made alkaline by the addition of 0.1 M NaOH (100 µl). Concentrations of DBSP in bile samples were determined in a spectrophotometer (Spectramax M2, Molecular
Devices, Sunnyvale, CA) at a wavelength of 570 nm (Sathirakul et al., 1993) .
Blood samples were thawed on ice. Two volumes of acetonitrile containing formic acid (0.1% (v/v)) were added to the samples and standard solutions. Labetolol (Sigma Co., St Louis, MO) was added as an internal standard. After mixing, the contents were centrifuged at 1800 g for 10 min. 
Determination of DBSP pharmacokinetic parameters
Pharmacokinetic parameters of DBSP were calculated using Watson software (version 6; Watson Software System) with non-compartmental models.
Statistical analysis
Student t-Tests were used to determine the significance of differences between groups of animals. Differences with P values <0.05 or <0.01 were considered significant.
This article has not been copyedited and formatted. The final version may differ from this version. Figure 1B , lane 2), whereas a strong signal was observed in the membranes isolated from wild type mice (lane 1). Overall, no gross abnormalities were observed in the Mrp2 -/-mice, their life span was normal and mice were born at the expected Mendelian ratio. Table 1 shows the values for several clinical chemical parameters measured in serum. No significant increases were observed in ALT and AST between Mrp2 -/-and wild type mice, suggesting no hepatocellular damage in livers of knockout mice. Total bilirubin levels were 5-fold higher in knockout animals. In Mrp2 -/-mice, 60% of total (conjugated plus unconjugated) bilirubin was conjugated (direct) bilirubin, whereas the level of conjugated bilirubin in serum of wild type mice was below the limit of quantitation. Cholesterol levels were 1.5-fold higher in male knockout animals, but no significant change was observed between female Mrp2 -/-and control mice. The increased cholesterol level in male Mrp2 -/-mouse serum did not result in changes in the biliary excretion of cholesterol (data not shown). No significant differences were found in any of the other parameters measured, except for a slightly decreased alkaline phosphatase level in Mrp2 -/-compared to control female mice.
Serum analysis of Mrp2 -/-mice
Urine analysis of Mrp2 -/-mice
Part of conjugated bilirubin was excreted into the urine in TR -rats (Jansen et al., 1985) . To determine whether this was also the case in mice, total and direct bilirubin amounts in urine were measured (Table 2 ). In urine collected over a 12 h time period, levels of direct bilirubin were 6.7-fold higher in Mrp2 -/-mice. The other urine parameters measured were not changed significantly.
Glutathione levels in Mrp2 -/-mice Paulusma et al. (1999) found previously that the biliary excretion of glutathione was reduced strongly in TR -rats, suggesting that Mrp2 was involved in the transport of glutathione. Therefore, the biliary excretion of glutathione in mice was measured ( Figure   2A ). The biliary excretion rate of glutathione was 16-fold lower in Mrp2 -/-than in controls (25 nmol/kg/min in Mrp2 -/-versus 400 nmol/kg/min in wild type mice). Some very low glutathione export was still detectable in knockout mice, suggesting the presence of other compensatory (unknown) canalicular glutathione transporters. The reduced excretion of glutathione in the knockout mice correlated with a 3-fold increased glutathione level in Mrp2 -/-liver extracts ( Figure 2B ). Differences in plasma levels of glutathione between Mrp2 -/-and control mice were not statistically significant ( Figure   2C ).
Bilirubin glucuronide levels in Mrp2 -/-mice
As physiologically important substrates of Mrp2, biliary secretion of endogenous bilirubin glucuronides in Mrp2 -/-mice was evaluated. As shown in Figure 2D , the biliary excretion rate of bilirubin glucuronides was about 2-fold lower in Mrp2 -/-mice than that in control mice. This is in agreement with reports that the biliary excretion of bilirubin and bilirubin glucuronides in EHBR and TR -rats is only decreased mildly (Jansen et al., 1985; Kurisu et al., 1991; Paulusma et al., 1999) .
This article has not been copyedited and formatted. The final version may differ from this version. Figure 3D ), resulting in a significant increase in the area under the curve (AUC) and a decrease in blood clearance (CL b ) in the knockout mice (Table 3 ). In line with these findings, in bile duct catheterized mice, the biliary excretion rate of DBSP (5 mg/kg, i.v.) was slower in knockout than in wild type mice ( Figure 3A ). Cumulative excretion of DBSP in bile indicated that almost 100% of the dose was excreted at t = 50 min in wild type animals, whereas only 25% was recovered in the Mrp2 -/-mice at the same time point. This percentage increased to 70% at 90 min. Bile flow was somewhat variable between the different time points ( Figure 3C ), but on average ~25% lower in Mrp2 -/-than in wild type mice. Taken together, these data demonstrated that Mrp2 was contributing significantly to the elimination of DBSP. Most likely, the delayed appearance of DBSP in Mrp2 -/-mice relates to the fact that sinusoidal efflux is enhanced (see discussion).
Gene expression profiling in Mrp2 -/-liver, kidney, and intestine
A general concern in the use of transporter knockout animals for pharmacokinetic studies is the potential for induction of compensatory mechanisms which may complicate the interpretation of data obtained with such animals. Using TaqMan Low-Density Microarrays (Microfluidic Cards), we therefore determined the expression level of a total of ninety five Phase I, Phase II, transporter and a number of other genes relevant to drug metabolism in liver, intestine and kidney of wild type and Mrp2 -/-female and male mice (Tables 4-1 The Mrp2 mRNA level was 30-1000-fold lower in liver, kidney and intestine from Mrp2 -/-than in the corresponding organs from control mice, confirming that the Mrp2 gene was inactivated in the knockout mice. The low RNA signal detected in tissues from Mrp2 -/-mice was probably due to the presence of an unstable RNA transcript, which still may be formed as the Mrp2 promoter was not disrupted in these mice.
In humans and rats in which MRP2/Mrp2 activity is impaired or absent, MRP3/Mrp3 mRNA is induced in the liver (Hirohashi et al., 1998; Konig et al., 1999) . In contrast, no induction of Abcc3 (Mrp3) mRNA was observed in liver of either female or male Mrp2 -/-mice (Table 4 -1). Interestingly, Mrp4 (Abcc4) mRNA was induced 6-7-fold in liver of male and female Mrp2 -/-mice. In females, a 2.5-fold lower level of Slc22a7 (Oat2) was found in the liver of knockout versus wild type mice, whereas no significant differences were detected for any of the other transporter genes analyzed.
In kidney, expression of Mrp4 was increased 2.5-fold in male and female Mrp2
-/-mice. Expression of Abcb9, Slco1a1 (Oatp1) and Slco1a6 (Oatp5) was higher in males than in females. In female kidney, expression of Abcc3 was higher than in male kidney.
Of the cytochrome P450 genes analyzed, Cyp2b13 was expressed at a 10-fold lower level in liver of female Mrp2 -/-than in wild type mice (Table 4 -2). Cyp2b9 was expressed at a 2-fold lower level in female liver of the knockout mice. The cholesterol-7α-hydroxylase Cyp7a1 gene was expressed 2.2-fold higher in male Mrp2 -/-liver, and
Cyp4a14 in male Mrp2 -/-liver was expressed 2.5-fold lower than in liver from control mice. Cyp4a14 in male Mrp2 -/-kidney was expressed 2-fold lower than in wild type kidney. Expression of Cyp2d9, and Cyp4a12 was higher in male than in female liver, whereas expression of Cyp2b13, Cyp2b9, Cyp3a16 and Cyp3a41 was higher in female liver. In kidney, expression of Cyp2d9, and Cyp4a12 was higher in males than in females.
This article has not been copyedited and formatted. The final version may differ from this version. For the UDP-glucuronosyltransferase (UGT), glutathione S-transferase and sulfotransferase (SULT) genes analyzed, no significant differences were found between wild type and knockout mice (Table 4 -2). Expression of Ugt1a1 was higher in female than in male kidney, and expression of Ugt8 was higher in female then in male kidney.
As nuclear receptors play an important role in the regulation of gene expression, the expression of several nuclear receptors, including the pregnane X receptor (Pxr, Nr1i2), the constitutive androstane receptor (Car, Nr1i3), the liver X receptor (Lxr, Nr1h3), and the farnesoid X receptor (Fxr, Nr1h4) were evaluated. No significant differences were detected for these genes in the liver, kidney and intestine of knockout versus control mice (Table 4 -2).
Mrp4 protein levels in liver and kidney
Since Mrp4 mRNA was increased in both liver and kidney of Mrp2 -/-mice, protein levels were determined in crude membrane extracts of male mice by Western blotting.
Mrp4 was detected with monoclonal antibody M 4 I-10. By comparing the Western blot signal after loading various amounts of protein, Mrp4 protein was found to be increased 7-10-fold in liver of Mrp2 -/-mice ( Figure 4A ). In kidney the Mrp4 level was increased 2-fold in Mrp2 -/-mice ( Figure 4B , lanes 3-6). The Mrp4 level in wild type kidney was ~12-fold higher than in wild type liver ( Figure 4B , compare lanes 1 and 3).
Bile salt levels in bile and plasma
Since Mrp4 is localized to the basolateral membrane in hepatocytes and has been demonstrated to transport bile salts and conjugated bile acids in vitro (Rius et al., 2003) , total bile salt levels were measured in serum of male Mrp2 -/-and control mice.
Although bile salt levels were higher in serum of some Mrp2 -/-mice, variation was high and not statistically different from control mice (data not shown). Bile salt levels were also measured in bile. Over a 60 min sampling period, the excretion rate was somewhat 
Liver microsomal cytochrome P450 enzyme activities
To investigate whether the reduced expression of Cyp2b13 in liver of female
Mrp2
-/-mice resulted in a phenotypic effect and to confirm the lack of clear induction or suppression in the level of expression of any of the other P450 isoforms tested (Table 4- 2), we investigated P450-mediated enzyme activities in liver microsomes isolated from Mrp2 -/-and wild type male and female mice. While the specificity of probe substrates for all of the mouse P450 enzymes have not been clearly identified, it has been inferred that in mouse liver microsomes EROD and PROD activities are mediated by Cyp1A and Cyp2B, respectively, whereas testosterone 6β-hydroxylase (HT) activity is mediated by Cyp3A, 2α HT activity by Cyp2C, 16α HT activity by Cyp2D9 and Cyp2B, 7α HT activity by Cyp2A, and 16β HT by Cyp2B (Sapone et al., 2003) . Table 5 shows that no significant differences were detected in liver microsomes from wild type versus knockout mice. Some gender different activities were detected: 16α HT activity was higher in male than in female mouse liver microsomes, and PROD activity was lower in male than in female liver microsomes.
Taken together, these data suggest no significant differences in major P450
enzyme activities between the Mrp2 -/-and wild type mice.
This article has not been copyedited and formatted. The final version may differ from this version. The relatively strong Induction of Mrp4 protein in liver ( Figure 4A ) of Mrp2 -/-mice was unexpected as this has not been found in TR -rats . MRP4 is (Assem et al., 2004 ). We did not find activation of other CAR target genes, however, like for instance Cyp2b10 (Table 4 -2).
In the Mrp2 -/-mice, total and conjugated bilirubin in serum were increased 5-and >3-fold, respectively (Table 1) , and in urine conjugated bilirubin was increased 6.7-fold (Table 2 ). In TR -/EHBR rats the level of bilirubin conjugates in plasma was 50-100 times higher than in Wistar or SD rats, respectively (Hosokawa et al., 1992; Jansen et al., 1985) . Jansen et al. also showed that bilirubin and bilirubin conjugates are excreted via the urine in TR -rats, whereas no excretion was detected in Wistar rats. It was (Table 2) . If more efficient in mice than in rats (e.g., via Mrp4), this could result in lower plasma levels.
Differences in cytochrome P450 activities have been found between TR -/EHBR and wild type rats (Jager et al., 1998; Newton et al., 2005) . One of the reasons to characterize the Mrp2 -/-mice was to use these animals to study the role of Mrp2 in the pharmacokinetics of drugs. It therefore was important to investigate whether differences in results between knockout and control mice could not only be explained by the lack of Mrp2 but potentially also by differences in phase I enzymatic activities. Based on the phenotypic and mRNA expression analysis (Tables 4-2 and 5), no significant differences were found in P450 enzyme activities or mRNA levels in male mice. In female mice
Cyp2b13 was 10-fold lower in Mrp2 -/-than in control liver. Based on PROD and 16α-HT activities this did not translate into a phenotypic effect, however.
Bile duct cannulation studies with the Mrp2 model substrate DBSP were performed to demonstrate that Mrp2 was functionally absent in the knockout mice (Figure 3 ). DBSP was chosen as it is a non-metabolized Mrp2 substrate (Klaassen, 1970) , and it has been shown previously that the biliary excretion rate and plasma clearance of DBSP in both TR -and EHBR rats was impaired (Jansen et al., 1987; Sathirakul et al., 1993) . Residual transport was detected, however, in the mutant rats which suggested that other transporters in the canalicular membrane transport DBSP. In the Mrp2 -/-mice, we observed a delayed and reduced biliary excretion rate of DBSP in bile ( Figure 3A) . As in EHBR/TR -rats, the residual excretion of DBSP in the knockout We found that in the knockout mice the biliary excretion of DBSP started to decrease after 50 min ( Figure 3A ), although at that time point only 30% of the dose had been excreted ( Figure 3B ). As the bile flow was relatively constant over this time frame ( Figure 3C ), this suggested that after the intrahepatic DBSP concentration reached a certain threshold, DBSP was transported back into the blood. This may be via Mrp3, Mrp4, or via an Oatp as it has been shown for rat Oatps that they can act bidirectionally (Li et al., 2000) .
In normal rats, excretion of glutathione into bile is high and this transport is almost absent in TR -rats (Paulusma et al., 1999) . In line with this finding, we also found that excretion of glutathione was reduced significantly in Mrp2 -/-mice compared to control mice (Figure 2A) . In our measurements, we detected both reduced and oxidized glutathione, but levels of the latter are usually very low (Paulusma et al., 1999) . Uptake experiments with membrane vesicles have suggested that GSH is a substrate for human and rat MRP2/Mrp2 with an apparent K m in the mM range (Paulusma et al., 1999) . GSH This article has not been copyedited and formatted. The final version may differ from this version. (Ballatori et al., 2005) . We also found that biliary excretion of bilirubin glucuronides was only mildly decreased in Mrp2 -/-mice ( Figure 2D ), suggesting the involvement of other transporters on biliary excretion of bilirubin glucuronides.
In summary, we have characterized Mrp2 -/-mice. These mice did not show differences in P450 enzyme levels in liver or induction of Mrp3. Mrp4 was increased in the Mrp2 -/-mice, however, especially in liver. Since the Mrp2 -/-mice show differences with TR -/EHBR rats, we expect that these mice will be a valuable additional tool to study the role of Mrp2 in the absorption and disposition of drugs.
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Data represent means ± SE determined from urine samples obtained from 5 groups of animals; each group included 3 animals as described in Materials and Methods.
Glucose (mg/dl/ml) 3.6 ± 1.6 4.0 ± 1.1 2.1 ± 0.4 3.8 ± 1.0
Urea nitrogen (mg/dl/ml) 496 ± 223 508 ± 145 252 ± 49 415 ± 110
Creatinine (mg/dl/ml) 8.7 ± 4.0 9.4 ± 2.4 3.8 ± 0.6 6.5 ± 1.7
Total protein (g/dl/ml) 0.3 ± 0.1 0.3 ± 0.1 0.04 ± 0.01 0.1 ± 0.01
Total bilirubin (mg/dl/ml) 0.7 ± 0.3 0.7 ± 0.2 0.4 ± 0.1 0. 
